Nothing Special   »   [go: up one dir, main page]

CY1119269T1 - Θεραπεια βλαβων που προκαλουνται απο ιους - Google Patents

Θεραπεια βλαβων που προκαλουνται απο ιους

Info

Publication number
CY1119269T1
CY1119269T1 CY20161100164T CY161100164T CY1119269T1 CY 1119269 T1 CY1119269 T1 CY 1119269T1 CY 20161100164 T CY20161100164 T CY 20161100164T CY 161100164 T CY161100164 T CY 161100164T CY 1119269 T1 CY1119269 T1 CY 1119269T1
Authority
CY
Cyprus
Prior art keywords
virus
treatment
caused damage
papilloma virus
lesions
Prior art date
Application number
CY20161100164T
Other languages
English (en)
Inventor
Steven Martin Ogbourne
Andreas Suhrbier
James Harrison Aylward
Original Assignee
Leo Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39925109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119269(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2007902266A external-priority patent/AU2007902266A0/en
Application filed by Leo Laboratories Limited filed Critical Leo Laboratories Limited
Publication of CY1119269T1 publication Critical patent/CY1119269T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται γενικά με την θεραπεία δερματικών βλαβών που περιέχουν κύτταρα μολυσμένα από ένα ιό, καθώς και με συνθέσεις για την θεραπεία τέτοιων βλαβών. Ειδικότερα η εφεύρεση σχετίζεται με ενώσεις ingenol, ειδικότερα ingenol angelates, στην θεραπεία βλαβών που προκαλούνται από μόλυνση με ένα ιό papilloma virus, όπως ένα ιό papilloma virus θηλαστικού, ειδικότερα ένα Ανθρώπινο Ιό Papilloma Virus.
CY20161100164T 2007-04-30 2016-02-29 Θεραπεια βλαβων που προκαλουνται απο ιους CY1119269T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007902266A AU2007902266A0 (en) 2007-04-30 Treatment of virally induced lesions
PCT/AU2008/000596 WO2008131491A1 (en) 2007-04-30 2008-04-30 Treatment of virally induced lesions

Publications (1)

Publication Number Publication Date
CY1119269T1 true CY1119269T1 (el) 2018-02-14

Family

ID=39925109

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100164T CY1119269T1 (el) 2007-04-30 2016-02-29 Θεραπεια βλαβων που προκαλουνται απο ιους

Country Status (22)

Country Link
US (1) US9895334B2 (el)
EP (1) EP2152261B1 (el)
JP (1) JP5497629B2 (el)
KR (1) KR101485883B1 (el)
CN (1) CN101742996B (el)
AU (1) AU2008243705B2 (el)
BR (1) BRPI0810806A2 (el)
CA (1) CA2685473C (el)
CY (1) CY1119269T1 (el)
DK (1) DK2152261T3 (el)
ES (1) ES2564173T3 (el)
HR (1) HRP20160181T1 (el)
HU (1) HUE028713T2 (el)
IL (1) IL201796A (el)
MX (1) MX2009011865A (el)
MY (1) MY154484A (el)
NZ (1) NZ580702A (el)
PL (1) PL2152261T3 (el)
RU (1) RU2506951C2 (el)
SI (1) SI2152261T1 (el)
UA (1) UA98328C2 (el)
WO (1) WO2008131491A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
NZ554710A (en) 2004-12-13 2010-03-26 Peplin Research Pty Ltd Treatment of solid cancers with angeloyl substituted ingenanes
NZ580702A (en) 2007-04-30 2012-03-30 Leo Lab Ltd Treatment of virally induced lesions
WO2010091472A1 (en) * 2009-02-13 2010-08-19 Peplin Research Pty Ltd Skin treatment
ES2633814T3 (es) * 2010-04-16 2017-09-25 Leo Pharma A/S Mebutato de ingenol cristalino ortorrómbico
US9402823B2 (en) 2010-12-17 2016-08-02 Leo Laboratories Limited Ingenols for treating seborrheic keratosis
CN103402969A (zh) * 2010-12-22 2013-11-20 利奥实验室有限公司 3-酰基-巨大戟二萜醇ii
TWI548616B (zh) * 2010-12-22 2016-09-11 理奧實驗有限公司 巨大戟萜醇－３－醯化物iii及巨大戟萜醇－３－胺基甲酸酯化物
AU2011347261A1 (en) * 2010-12-22 2013-07-11 Leo Laboratories Limited Ingenol-3-acylates I
WO2012176015A1 (en) 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
KR101406201B1 (ko) 2011-10-19 2014-06-12 한국생명공학연구원 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
AU2013225633B2 (en) 2012-03-02 2017-11-23 Amazonia Fitomedicamentos Ltda. Ingenol derivatives in the reactivation of latent HIV
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
AU2013283511B2 (en) * 2012-06-26 2017-10-26 Leo Laboratories Limited 3-O-heteroaryl-ingenol
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
US20150320679A1 (en) * 2012-12-12 2015-11-12 Leo Laboratories Limited Gel compositions
GB201222403D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
GB201222406D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
US20160120835A1 (en) * 2013-06-12 2016-05-05 Leo Laboratories Limited A topical composition
KR101520428B1 (ko) * 2013-11-22 2015-05-14 충남대학교산학협력단 대극 추출물을 유효성분으로 포함하는 항인플루엔자용 조성물
CN104188979B (zh) * 2014-08-11 2017-01-11 泰州祥泰康华医药科技有限公司 闭花木酮Cleistanone的O-(吗啉基)乙基衍生物在制备治疗缺血性脑损伤药物中的应用
CN104523705A (zh) * 2014-12-10 2015-04-22 南京大学 闭花木酮的o-(咪唑基)乙基衍生物在制备抗病毒药物中的应用
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
JP7495679B2 (ja) * 2019-10-03 2024-06-05 国立大学法人京都大学 ヒトパピローマウイルス性疣贅に対する貼付剤
EP3915549A1 (en) * 2020-05-26 2021-12-01 Merck Patent GmbH Senescence inducers for use in the treatment and/or prevention of virus induced diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804203A (en) * 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
RU2174396C2 (ru) * 1997-03-20 2001-10-10 Панацея Биотек Лтд. Фармацевтическая композиция для подавления и лечения аноректальных и ободочно-кишечных болезней
AUPQ801700A0 (en) * 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
NZ554710A (en) * 2004-12-13 2010-03-26 Peplin Research Pty Ltd Treatment of solid cancers with angeloyl substituted ingenanes
CA2629337A1 (en) * 2005-11-14 2007-05-18 Peplin Research Pty Ltd Use of angeloyl-substituted ingenanes in combination with other agents to treat cancer
GB0525680D0 (en) * 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
NZ580702A (en) 2007-04-30 2012-03-30 Leo Lab Ltd Treatment of virally induced lesions

Also Published As

Publication number Publication date
BRPI0810806A2 (pt) 2014-10-29
WO2008131491A1 (en) 2008-11-06
AU2008243705A1 (en) 2008-11-06
CN101742996B (zh) 2013-08-21
DK2152261T3 (en) 2016-03-07
NZ580702A (en) 2012-03-30
MX2009011865A (es) 2009-12-04
ES2564173T3 (es) 2016-03-18
AU2008243705B2 (en) 2013-10-10
RU2506951C2 (ru) 2014-02-20
HK1134450A1 (zh) 2010-04-30
KR20100017464A (ko) 2010-02-16
MY154484A (en) 2015-06-30
CN101742996A (zh) 2010-06-16
UA98328C2 (uk) 2012-05-10
PL2152261T3 (pl) 2016-06-30
US20100204318A1 (en) 2010-08-12
RU2009144100A (ru) 2011-06-10
IL201796A (en) 2016-11-30
EP2152261B1 (en) 2015-12-09
CA2685473A1 (en) 2008-11-06
JP2010524978A (ja) 2010-07-22
HRP20160181T1 (hr) 2016-05-06
HUE028713T2 (en) 2016-12-28
JP5497629B2 (ja) 2014-05-21
KR101485883B1 (ko) 2015-01-27
EP2152261A1 (en) 2010-02-17
SI2152261T1 (sl) 2016-05-31
EP2152261A4 (en) 2013-01-02
CA2685473C (en) 2015-09-01
US9895334B2 (en) 2018-02-20
IL201796A0 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
CY1119269T1 (el) Θεραπεια βλαβων που προκαλουνται απο ιους
CY1119988T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1119684T1 (el) Αντι-ιικες ενωσεις
MA33939B1 (fr) 5-alcynyl-pyrimidines
CY1112999T1 (el) Αναστολεις ιου ηπατιτιδας c
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
ECSP12012147A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales
CY1113449T1 (el) Αντι-ιικες συνθεσεις που περιλαμβανουν γερανιολη και καρβονη
CY1113259T1 (el) Ιμιδαζολυλο διφαινυλο ιμιδαζολια ως αναστολεις ιου ηπατιτιδας c
UA97834C2 (ru) Производные сульфониламида для лечения анормального роста клеток
CY1117705T1 (el) Νεες ενωσεις διυποκατεστημενης 3,4-διαμινο-3-κυκλοβουτενο-διονης-1,2 για χρηση στην θεραπεια προκαλουμενων απο χημειοκινη ασθενειων
EA201190306A1 (ru) Улучшенная липидная композиция
EA201100564A1 (ru) Антипролиферативные соединения
EA201791850A1 (ru) Борсодержащие малые молекулы
CU20100032A7 (es) Depsipéptidos cíclicos
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
EA201201623A1 (ru) Лечение диабета 2 типа
UA107562C2 (uk) Спосіб лікування псоріазу
MX391620B (es) Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
EA201001427A1 (ru) Тиазолилдигидроиндазолы
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.